Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for hematologic malignancies. Its pipeline includes Tamibarotene, a selective retinoic acid receptor alpha agonist being studied in Phase III for a genomically defined subset of patients with myelodysplastic syndrome and in Phase II for acute myeloid leukemia. The company is also advancing SY-2101, an oral formulation of arsenic trioxide for acute promyelocytic leukemia, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I studies for selected advanced solid tumors. Formerly known as LS22, Inc., the company adopted its current name in August 2012 and was incorporated in 2011. Syros Pharmaceuticals is headquartered in Cambridge, Massachusetts, and its common stock trades on OTC Markets under the symbol SYRS.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.